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The pathogenesis of neurological diseases and disorders remains mostly unknown. Neuroinflammation has been 
proposed as a causative factor for neurological diseases. The confirmation that neurogenesis occurs in the adult 
brain and neural stem cells (NSCs) reside in the adult central nervous system (CNS) of mammals has tremendous 
implications for our understanding of the physio- and pathology of the nervous system. The generation of 
newborn neuronal cells in the adult brain is modulated in neurological diseases and during inflammation. This 
suggests that adult neurogenesis is involved in the pathogenesis of neurological diseases and disorders, 
particularly during neuroinflammation. In this manuscript, we will review the modulation of adult neurogenesis 
in neurological diseases and during neuroinflammation. We will discuss the role and contribution of 
neuroinflammation and adult neurogenesis to neurological diseases and disorders, and for the therapeutic 
potential of adult NSCs. 
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Introduction 
Neuroinflammation is a process in which the 
brain responds to infections, diseases and injuries [1, 
2]. Neuroinflammation involve two types of immune 
cells: lymphocytes, monocytes and macrophages of the 
hematopoietic system, and microglial cells of the CNS 
[3, 4]. Neuroinflammation disrupts the blood-brain 
barrier (BBB), allowing cells from the hematopoietic 
system to leave the blood stream and come in contact 
to the injury site [5]. The immune cells respond to 
injuries by eliminating debris and, synthesizing and 
releasing a host of powerful regulatory substances, like 
the complements, cytokines, chemokines, glutamate, 
interleukins, nitric oxide, reactive oxygen species and 
transforming growth factors [6-10]. The substances 
have both beneficial and harmful effects on the cellular 
environment, creating further damages [11] (fig. 1). 
Mature astrocytes are also activated following injury to 
the CNS [12, 13]. Astrocytic activation is believed to be 
necessary for containing the immune response, 
repairing the BBB and attenuating further neuronal 
death [5, 14]. 
Contrary to a long-held dogma, neurogenesis 
occurs in the brain and NSCs reside in the CNS of 
adult mammals, in various species including human 
[15, 16]. NSCs are the self-renewing multipotent cells 
that generate the main phenotypes of the nervous 
system. Neurogenesis is modulated in the brain of 
patients and in animal models of neurological diseases 
and disorders, like Alzheimer’s disease (AD), epilepsy 
and Huntington’s disease (HD) [17]. This suggests that 
the adult brain may be amenable to repair and that 
adult neurogenesis may contribute to the functioning, 
and phyio- and pathology of the CNS, particularly to 
the etiology of neurological diseases and disorders. 
Neuroinflammation in neurological diseases 
and injuries 
  Inflammation is a process in which the body's 
white blood cells and chemicals protect us, from 
infections, foreign substances and injuries. In the CNS, 
neuroinflammation occurs following traumatic brain 
injuries, spinal cord injuries and cerebral strokes. It 
involves immune cells from the hematopoietic and 
nervous system [1, 2, 6, 18]. It is now well documented 
that neuroinflammation is actively involved in 
neurological diseases and disorders, like AD, 
amyotrophic lateral sclerosis, depression, epilepsy, 
HD, multiple sclerosis and Parkinson’s disease (PD) 
[19-22]. Particularly, in AD, there is a correlation 
between local inflammation, and presence of amyloid 
plaques and neurofibrillary tangles [23]. 
It is proposed that chronic inflammation is a 
causative factor to the pathogenesis of neurological 
diseases and disorders [20, 24] (fig. 1). The immune Int. J. Med. Sci. 2008, 5 
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cells and pro-inflammatory chemicals involved in 
neuroinflammation would underlie the mechanisms of 
diseases and neurodegeneration. The activation, or 
over activation, of immune cells involved in 
neuroinflammation and release of pro-inflammatory 
substances would result in reduced neuroprotection 
and neuronal repair, and increased 
neurodegeneration, leading to neurodegenerative 
diseases [10, 25, 26]. Depression is a common 
antecedent to many neurological diseases, particularly 
neurodegenerative diseases like AD and PD [27, 28]. 
Chronic inflammation during depressive episodes 
could predispose depressive patients to 
neurodegenerative diseases, later in life [29]. 
 
 
Figure 1. Adult neurogenesis and neuroinflammation. 
Neuroinflammation has been proposed as a causative factor for 
neurological diseases and disorders. It has both beneficial and 
harmful effects on the cellular environment. Neuroinflammation 
disrupts the BBB. Adult neurogenesis in modulated in a broad 
range of neurological diseases and disorders; it is decreased 
during inflammation. Adult neurogenesis may be involved in 
regenerative attempts and the plasticity of the nervous system. 
Adult-derived neural progenitor and stem cells grafted in the 
brain promote neuroprotection, by an immunomodulatory 
mechanism. Grafted neural progenitor and stem cells interact 
with the host immune system to promote functional recovery, an 
interaction that may provide clinical benefit for NSC-based 
therapy. 
 
Adult neurogenesis, neural stem cells and 
cellular therapy 
In the adult mammalian brain, including in 
humans, neurogenesis occurs primarily in two regions, 
the dentate gyrus (DG) of the hippocampus and 
subventricular zone (SVZ) [30, 31]. Neurogenesis 
involves a relatively small number of cells, particularly 
in the DG, and is modulated by environmental stimuli, 
trophic factors/cytokines, drug treatments, and in 
various physio- and pathological conditions, like 
neurological diseases and disorders [32]. Newborn 
neuronal cells, in the adult brain, establish functional 
connections, survive for extended period of time, at 
least 2 years in human, and reproduce processes 
similar to development, to integrate the mature 
network [30, 33, 34]. Adult neural progenitor and stem 
cells have been isolated and characterized in vitro, 
from various species [16], including from human 
biopsies and post-mortem tissues [35]. It is 
hypothesized that newborn neuronal cells in the adult 
brain originate from residual stem cells. The existence 
of stem cells in the adult brain suggests that it has the 
potential for self-repair and that newborn neuronal 
cells may contribute to the functioning, and physio- 
and pathology of the CNS [36]. However, adult NSCs 
remain elusive cells and to be unequivocally identified 
and characterized in vitro and in vivo [37, 38]. 
Two strategies are being considered for adult 
NSC-based therapy in the CNS, the stimulation of 
endogenous neural progenitor or stem cells and the 
transplantation of adult-derived neural progenitor and 
stem cells [39]. Self-renewing multipotent neural 
progenitor and stem cells have been isolated and 
characterized in vitro, from various regions of the 
adult mammalian CNS, including the spinal cord [16]. 
This suggests that neural progenitor and stem cells 
reside throughout the adult CNS, in mammals. The 
stimulation of endogenous neural progenitor or stem 
cells locally would represent a strategy to promote 
regeneration of the diseased and injured nervous 
system. Alternatively, new neuronal cells are 
generated at sites of degeneration in the diseased brain 
and after CNS injuries, like in HD and in experimental 
models of cerebral strokes 40, 41]. These cells originate 
from the SVZ and migrate partially through the 
rostro-migratory stream to the sites of degeneration. 
This suggests that strategies to promote regeneration 
and repair may focus on stimulating SVZ 
neurogenesis. Adult derived-neural progenitor and 
stem cells may be transplanted locally [42] or 
administered intravenously to promote regeneration 
and repair [43]. Systemic injection provides a model of 
choice for delivering adult derived-neural progenitor 
and stem cells for the treatment of neurological 
diseases and injuries, where the degeneration is 
widespread, like AD and HD. 
Adult neurogenesis in neurological diseases and 
disorders 
Adult neurogenesis is modulated in the brains of 
patients and in animal models of neurological diseases 
and disorders, like AD, depression, epilepsy, 
Huntington’s and Parkinson’s diseases [17]. 
Neurogenesis is increased in the hippocampus of Int. J. Med. Sci. 2008, 5 
 
129
brains of patients with AD, as revealed after autopsies 
by an increase in the expression of markers for 
immature neuronal cells, like doublecortin and 
polysialylated nerve cell adhesion molecule, in 
hippocampal regions [44]. In animal models of AD, 
neurogenesis is increased in the DG of transgenic mice 
expressing the Swedish and Indiana amyloid protein 
precursor (APP) mutations, a mutant form of human 
APP, [45] and decreased in the DG and SVZ of 
knock-out mice for presenilin 1 and APP [46, 47]. This 
shows that adult neurogenesis is enhanced in AD 
brains. The discrepancies observed on adult 
neurogenesis in brain autopsies of patients with AD 
and animal models of AD may originate from the 
limitations of animal models, particularly transgenic 
mice, as representative models of complex diseases, 
particularly AD [48] and to study adult phenotypes, 
like adult neurogenesis. Result from autopsies reveals 
that neurogenesis is not altered in the brains of 
depressive patients [49]. Neurogenesis is enhanced in 
the DG and SVZ of animal models of epilepsy, like 
after pilocarpine treatment [50]. After pilocarpine 
treatment, ectopic granule-like cells in the hilus are 
labeled for bromodeoxyuridine (BrdU). BrdU is a 
thymidine analog that incorporates DNA of dividing 
cells during the S-phase of the cell cycle and is used for 
birthdating and monitoring cell proliferation [51]. 
MF-like processes immunostained for TOAD-64, a 
marker for newly generated neuronal cells, are also 
detected in the granule cell layer of the stratum oriens of 
CA3 and the inner molecular layer of the DG, in 
rodents [50]. Low-dose, whole-brain, X-ray irradiation 
in adult rats, after pilocarpine treatment, inhibits 
neurogenesis, but does not prevent seizure-induced 
ectopic granule-like cells and MF sprouting [52]. 
Hence, neurogenesis is enhanced in the DG and SVZ in 
animal models of epilepsy and seizure-induced ectopic 
granule-like cells and MF sprouting arises not only 
from newborn neuronal cells, but also from mature 
dentate granule cells. Immunohistochemistry and 
confocal microscopy analysis of autopsies for markers 
of the cell cycle and neuronal differentiation, like 
proliferating cell nuclear antigen and β-tubulin, show 
that cell proliferation and neurogenesis are increased 
in the SVZ of brains of patients with HD [41]. In adult 
R6/1 transgenic mouse model of HD, neurogenesis 
decreases in the DG [53]. After quinolinic acid striatal 
lesioning of adult brain, neurogenesis is increased in 
the SVZ [54], as observed in brains of HD patients [41]. 
These data provide evidences that adult neurogenesis 
is increased in the SVZ of brains with HD. Data from 
R6/1 transgenic mouse model of HD are difficult to 
interpret in the context of adult neurogenesis in HD, as 
mutated forms of huntingtin affect brain development 
[55]. This could underlie the decrease of neurogenesis 
reported in adult transgenic mice R6/1. In PD, one 
study reports that the rate of neurogenesis, measured 
by BrdU labeling, is stimulated in the substantia nigra 
(SN), following lesion induced by a systemic dose of 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 
[56]. Another study reports no evidence of new 
dopaminergic neurons in the SN of 
6-hydroxydopamine-lesioned hemi-Parkinsonian 
rodents [57]. Hence, neurogenesis in the SN is the 
source of debates and controversies, and remains to be 
further evaluated. 
In all, adult neurogenesis in modulated in a broad 
range of neurological diseases and disorders (fig. 1). 
The contribution and significance of this modulation to 
the etiology and pathogenesis of neurological diseases 
and disorders remain mostly unknown. In epilepsy, 
low-dose, whole-brain, X-ray irradiation in adult rats, 
after pilocarpine treatment, inhibits neurogenesis, but 
does not prevent the induction of recurrent seizures 
[52]. These data provide a strong argument against a 
critical role of adult neurogenesis in epileptogenesis. 
However, although increased hippocampal 
neurogenesis may not be critical to epileptogenesis, it 
could be a contributing factor to limbic seizures when 
present. In depression, chronic administration of 
antidepressants, like the selective serotonin reuptake 
inhibitors fluoxetine, increases neurogenesis in the DG, 
but not the SVZ in adult rats, suggesting that adult 
neurogenesis is involved in the activity of 
antidepressants [58, 59]. X-irradiation of the 
hippocampal region, but not other brain regions, like 
the SVZ or the cerebellar region, inhibits neurogenesis 
and prevents the behavioral effect of the 
antidepressants, like fluoxetine, in adult mice [60]. 
Hence, it is proposed that adult neurogenesis mediate 
the activities of antidepressants, particularly selective 
serotonin reuptake inhibitors. In HD, in brains of HD 
patients and after quinolinic acid striatal lesioning of 
adult brain the enhanced neurogenesis in the SVZ 
leads to the migration of neuroblasts and formation of 
new neuronal cells in damaged areas of the striatum. 
This suggests that neurogenesis may be involved in 
regenerative attempts in HD brains [41, 54] (fig. 1).   
There are however debates and controversies 
over the modulation of adult neurogenesis in 
neurological diseases and disorders, particularly for 
studies involving BrdU labeling for studying 
neurogenesis. BrdU is a thymidine analog that 
incorporates DNA of dividing cells during the S-phase 
of the cell cycle and is used for birthdating and 
monitoring cell proliferation [51]. There are limitations 
and pitfalls over the use of BrdU for studying 
neurogenesis. BrdU is toxic and mutagenic substances. Int. J. Med. Sci. 2008, 5 
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It triggers cell death, the formation of teratomes, alters 
DNA stability, lengthens the cell cycle, and has 
mitogenic, transcriptional and translational effects on 
cells that incorporate it. BrdU is not a marker for cell 
proliferation, but a marker for DNA synthesis [61-63]. 
High level, 4 to 10%, of tetraploid nerve cells have been 
reported in regions in which degeneration occurs in 
AD, like the hippocampus [64]. It is proposed that cell 
cycle re-entry and DNA duplication, without cell 
proliferation, precede neuronal death in degenerating 
regions of the CNS [65]. Some of the data observed by 
mean of immunohistochemistry for cell cycle proteins 
and BrdU labeling in the brains of AD patients and in 
animal models of the disease, may therefore not 
represent adult neurogenesis, but rather labeled nerve 
cells that may have entered the cell cycle and 
underwent DNA replication, but did not complete the 
cell cycle [62]. In addition, many physio- and 
pathological processes, like exercise, neurological 
diseases and injuries, like AD, PD and cerebral strokes 
and drugs treatments affect the permeability of the 
BBB and cerebral flow [66-68]. Some of the data 
observed by mean of BrdU labeling in animal models 
of neurological diseases and after drug treatments may 
reflect bio-availability of BrdU in the brain, rather than 
neurogenesis. 
Neuroinflammation in adult neurogenesis 
Neuroinflammation inhibits neurogenesis in the 
adult hippocampus [69, 70] (fig. 1). The mechanism, 
function and significance of the modulation of 
neurogenesis during inflammatory processes remain 
to be elucidated. Molecules released by the immune 
cells, like interleukins and nitric oxide, regulate 
negatively adult neurogenesis and may underlie the 
molecular mechanisms of inflammatory reactions on 
adult neurogenesis [71, 72]. Neuroinflammation is 
actively involved in neurological diseases and 
disorders, like AD, depression and PD [19-22]. It is 
proposed that chronic inflammation is a causative 
factor to the pathogenesis of these neurological 
diseases and disorders [20, 24]. Hence, the modulation 
of adult neurogenesis during the inflammatory process 
may contribute or cooperate with the activity of 
neurological diseases and disorders on adult 
neurogenesis. Since the function of newborn neuronal 
cells is still the subject of debates and remains to be 
elucidated, the significance of the modulation of adult 
neurogenesis during inflammatory processes and in 
neurological diseases and disorders can only be 
speculated. Newborn neuronal cells may represent a 
regenerative attempt and contribute to the plasticity of 
the nervous system [73] (fig. 1). 
There are however debates and controversies 
over the modulation of adult neurogenesis during 
inflammatory processes, particularly for studies 
involving BrdU labeling for studying neurogenesis. 
Neuroinflammation alters the permeability of the BBB 
[5]. Hence, some of the data observed by mean of BrdU 
labeling in animal models during inflammatory 
processes may reflect bio-availability of BrdU in the 
brain, rather than neurogenesis. Investigators have 
used X-ray irradiation to inhibit neurogenesis and 
study the function of adult neurogenesis [52, 60, 74]. 
Brain irradiation induces inflammatory responses (fig. 
1). Hence, the effects of brain irradiation on adult 
neurogenesis in animal models, particularly of 
neurological diseases and disorders, are therefore 
difficult to interpret in light of these data. In all, the 
modulation of adult neurogenesis during 
inflammatory processes and after X-irradiation 
treatments remains to be further evaluated. 
Neural progenitor and stem cells express 
receptors, and respond to trophic factors and 
cytokines. Hence, the inflammation resulting from the 
pathological processes to be treated by the 
transplantation of neural progenitor and stem cells, as 
well as the transplantation procedure itself may have 
adverse effects of the success of the graft (fig. 1). The 
timing of transplantation in the diseased brain or after 
injury is therefore critical for successful transplantation 
of neural progenitor and stem cell therapy [75]. Studies 
reveal that adult-derived neural progenitor and stem 
cells promote neuroprotection, by an 
immunomodulatory mechanism [76] (fig. 1). Grafted 
neural progenitor and stem cells interact with the host 
to promote functional recovery, an interaction that 
may provide clinical benefit for NSC-based therapy 
(fig. 1). The interaction of grafted neural progenitor 
and stem cells with the immune system suggests that 
pre-clinical studies involving immuno-depressed mice 
may not represent an appropriate model to 
characterize and validate sources of human-derived 
neural progenitor and stem cells for therapy [77]. 
Conclusion and Perspectives 
Neuroinflammation is involved in the 
pathogenesis of neurological diseases and disorders, 
but its contribution and involvement to these 
pathological processes remain to be elucidated. It may 
be involved in the modulation of neurogenesis in 
neurological diseases and disorders, but the 
contribution and significance of this modulation 
r e m a i n  t o  b e  u n d e r s t o o d . Neuroinflammation has 
tremendous implications for cellular therapy. On the 
one hand, it may limit the therapeutic potential of 
adult NSCs in vivo and ex vivo. On the other hand, it 
may interact with the neurogenic niches to promote 
the regenerative potential in vivo, and the integration 
of the grated neural progenitor and stem cells ex vivo. Int. J. Med. Sci. 2008, 5 
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Hence, neuroinflammation may have both beneficial 
and detrimental effects on the potential of adult NSCs, 
to promote regeneration and repair in vivo and ex 
vivo. Therapeutic strategies for promoting the 
potential of adult NSCs in vivo and ex vivo may 
involve pro- and anti-inflammatory treatments. Future 
studies will aim at unraveling the molecular 
mechanisms governing the interaction between neural 
progenitor and stem cells and the immune system, and 
it implications for cellular therapy. 
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